GT Biopharma, Inc. (GTBP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.51
- As of
Kresmion compiles this page from GTBP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
GT Biopharma, Inc. (GTBP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-25.
See the full GTBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GTBP on one page. Preview it with sample data, then open it live with a free account.
Preview the GTBP dossierActive events for GTBP
- mediumEarnings below estimates
Q2-2026: Missed consensus by 47.1%, EPS $-0.12 vs $-0.0816 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 25.0% - EPS $-0.52 vs $-0.6936 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 103.8% - EPS $-0.79 vs $-0.3876 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 2056.9% - EPS $-4.84 vs $-0.2244 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 34.8% - EPS $-0.11 vs $-0.0816 estimate
FREE, NO ACCOUNT
Every event on GTBP, as it fires
New filings, 13F moves and cross asset events on GTBP land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, GTBP
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GTBP against its peers
GTBP's return on equity of -490.0% ranks in the 8th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | GTBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 391743 | n/a | 13 |
| Gross margin | n/a | 68.4% | n/a | 5 |
| Operating margin | n/a | -524.7% | n/a | 11 |
| Net margin | n/a | -859.5% | n/a | 12 |
| Return on equity | -490.0% | -109.8% | 8 | 19 |
Peers (24): PBM, CLRB, TVRD, ATYR, KPTI, CLGN, HIND, LSTA, LPCN, ZEOX, PASG, AEON, CNSY, GDTC, ASBP, BIVI, HEPA, ACTU, AAGH, INTS, PHIO, SYBX, TCRX, KPRX. Left out: VICP (period gap). Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (GTBP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GTBP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GTBP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.